Nigeria’s approval of the revised National Biotechnology Policy 2026 deserves more than a ceremonial welcome. It should mark the beginning of a deliberate effort to turn scientific knowledge into productive capacity, stronger industries and practical solutions to some of the country’s most persistent challenges.
The policy replaces a framework introduced in 2001, at a time when biotechnology was at a very different stage of development. 25 years later, technologies such as gene editing, genomics, precision agriculture and advanced manufacturing have created opportunities that Nigeria cannot afford to ignore.
We believe the strongest value of the revised policy lies in its emphasis on commercialisation and technology transfer. Nigeria has no shortage of researchers, universities or scientific ideas. The recurring weakness has been the distance between research institutions and the marketplace.
Too many innovations remain within laboratories, academic papers or pilot projects without becoming products that can improve lives or create businesses.
The new policy should change that.
We urge the federal government to make implementation measurable. The success of the policy should not be judged by the number of research projects approved or conferences held. It should be measured by technologies commercialised, startups created, patents translated into products, jobs generated and industries strengthened.
Agriculture provides an immediate opportunity.
Precision agriculture and climate-smart biotechnology can help farmers respond to changing weather conditions, improve productivity and strengthen food security. Nigeria cannot continue to rely largely on traditional production methods while its population and food demand expand.
Healthcare is another area where biotechnology could deliver transformative gains. Genomics, improved diagnostics and other biotechnology applications can strengthen domestic research and reduce dependence on imported solutions.
We are of the opinion that the policy must also encourage stronger partnerships between government, universities, research institutions and the private sector. Government cannot commercialise biotechnology alone. Investors need predictable policies, researchers need funding and industries need incentives to adopt locally developed technologies.
The Nigeria Biotechnology Partnership, which formalises the country’s participation in the Global Biotechnology Partnership, provides an important opening. We urge policymakers to use it to attract capital, expertise, technology and international partnerships that can strengthen local capacity rather than deepen dependence on foreign solutions.
There is also a human capital dimension.
Nigeria’s young population can become an important asset in the biotechnology economy if skills development is treated as a central part of implementation. Training should extend beyond researchers to technicians, entrepreneurs, engineers, data specialists and other professionals required to build a modern biotechnology ecosystem.
We believe President Bola Ahmed Tinubu’s approval provides the policy direction, but policy direction alone will not produce results. Sustained funding, transparent regulation, intellectual property protection, research infrastructure and incentives for private investment will determine whether the framework delivers.
The revised policy is therefore an opportunity to correct a long-standing gap in Nigeria’s development story.
The country must move from celebrating scientific potential to building economic value from it. Biotechnology can support food security, healthcare, industrial production and environmental sustainability. But its greatest contribution will come when Nigerian discoveries leave the laboratory and enter farms, hospitals, factories and markets.
That should be the real measure of this new policy.
